Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Aspen Japan Launches Paxil AG
September 9, 2016
- Ono Files Kyprolis for Multiple Myeloma as Combo Therapy with Dexamethasone
September 8, 2016
- Ono Rolls out Multiple Myeloma Treatment Kyprolis
September 8, 2016
- Biogen Japan’s Hemophilia Spinoff to Be Up and Running in Early 2017
September 8, 2016
- Sun Taps Mitsubishi Tanabe to Distribute Novartis’ 14 Established Brands
September 7, 2016
- Psoriasis Treatment Apremilast Achieves Primary Endpoint in Japan PIIb Trial: Celgene
September 7, 2016
- BIKEN, Kaketsuken to Develop Zika Virus Vaccines from Strain Isolated by Chiba Prefectural Institute of Public Health
September 7, 2016
- Mitsubishi Tanabe Applies for Partial Change to Remicade Dosage to Shorten Administration Interval in Crohn’s Disease
September 7, 2016
- Fujifilm Gets 10%-plus Stake in Australian Cell Therapy Startup
September 6, 2016
- Sato, Fuso to Copromote Emla Cream for Dialysis Patients
September 6, 2016
- Hisamitsu Starts PIII Trial of Transdermal Schizophrenia Treatment in US
September 6, 2016
- Celgene Seeks Japan Approval of Romidepsin for PTCL
September 6, 2016
- Merck Ditches Osteoporosis Med Odanacatib from Global Pipelines
September 6, 2016
- Sanofi’s PCSK9 Inhibitor Praluent Now Available in Japan
September 6, 2016
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Takeda to Develop Zika Vaccine with US Funding
September 5, 2016
- MSD Paid 15.2 Billion Yen to Doctors, Medical Institutions in 2015
September 5, 2016
- Oncolys to Evaluate Oncolytic Virus in Combination with Immune Checkpoint Inhibitors; Interim Results Expected in 2017
September 5, 2016
- Nippon Kayaku Seeks Add’l Dosage for Remicade Biosimilar in Psoriasis
September 2, 2016
- Takeda Kicks Off Global Observation Study for Multiple Myeloma
September 2, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…